INNO-LIPA^® HBV Multi-DR

Features & Benefits

• Earliest detection of mutants:
• Highly sensitive detection at single nucleotide level of mixtures of wild-type and mutants, identifying the appearance of mutants earlier than sequencing and viral load assays
• Lower limit of detection of 990 copies/ml
• Allowing rapid and effective HBV suppression by early adoption to the most suited therapy
• All the necessary information in one assay:
• Allows simultaneous detection of all clinically relevant HBV polymerase wild-type and drug-induced mutations associated with lamivudine, emtricitabine, telbivudine, adefovir and tenofovir resistance as well as known compensatory mutations (codons 80, 173, 180, 181, and 204)
• Identifies amino acid changes in the overlapping reading frame of HBsAg (codons 171, 172, 195, 196, 198, and 199)
• Optimized for 8 known HBV genotypes (A-H)
• Low chance of errors and limited hands-on time:
• Easy to perform and robust assay
• Amplicon can also be used for INNO-LIPA HBV GT
• Fully automated processing of the strips possible with Auto-LIPA™ 48 and AutoBlot 3000H.
• Objective and automated reading and interpretation of strips possible using LiRAS® for Infectious Diseases.